Prometic Life Sciences Inc., of Laval, Quebec, reported during the American Society of Nephrology meeting in Philadelphia preclinical data showing that PBI-4050, an oral, antifibrotic drug, attenuated development of diabetic nephropathies in type 2 diabetes through the improvement of glycemic control and the inhibition of renal TGFbeta-mediated fibrotic pathways, in association with disease in macrophage infiltration, oxidative stress and increase in autophagy.